Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Dec 4;105(23):1789-98.
doi: 10.1093/jnci/djt298. Epub 2013 Nov 14.

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial

Shuji Ogino  1 , Xiaoyun Liao, Yu Imamura, Mai Yamauchi, Nadine J McCleary, Kimmie Ng, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Renaud Whittom, Alexander Hantel, Al B Benson 3rd, Rex B Mowat, Donna Spiegelman, Richard M Goldberg, Monica M Bertagnolli, Jeffrey A Meyerhardt, Charles S Fuchs; Alliance for Clinical Trials in Oncology
Affiliations
Free PMC article
Randomized Controlled Trial

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial

Shuji Ogino et al. J Natl Cancer Inst. .
Free PMC article

Abstract

Background: Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer.

Methods: We examined associations of PIK3CA oncogene mutation with relapse, survival, and treatment efficacy in 627 stage III colon carcinoma case subjects within a randomized adjuvant chemotherapy trial (5-fluorouracil and leucovorin [FU/LV] vs irinotecan [CPT11], fluorouracil and leucovorin [IFL]; Cancer and Leukemia Group B 89803 [Alliance]). We detected PIK3CA mutation in exons 9 and 20 by polymerase chain reaction and pyrosequencing. Cox proportional hazards model was used to assess prognostic and predictive role of PIK3CA mutation, adjusting for clinical features and status of routine standard molecular pathology features, including KRAS and BRAF mutations and microsatellite instability (mismatch repair deficiency). All statistical tests were two-sided.

Results: Compared with PIK3CA wild-type cases, overall status of PIK3CA mutation positivity or the presence of PIK3CA mutation in either exon 9 or 20 alone was not statistically significantly associated with recurrence-free, disease-free, or overall survival (log-rank P > .70; P > .40 in multivariable regression models). There was no statistically significant interaction between PIK3CA and KRAS (or BRAF) mutation status in survival analysis (P(interaction) > .18). PIK3CA mutation status did not appear to predict better or worse response to IFL therapy compared with FU/LV therapy (P(interaction) > .16).

Conclusions: Overall tumor PIK3CA mutation status is not associated with stage III colon cancer prognosis. PIK3CA mutation does not appear to serve as a predictive tumor molecular biomarker for response to irinotecan-based adjuvant chemotherapy.

Trial registration: ClinicalTrials.gov NCT00003835.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves according to PIK3CA mutation in stage III colon cancers for recurrence-free survival (RFS) (A), disease-free survival (DFS) (B), and overall survival (OS) (C). Tables of the numbers of patients at risk are below the graphs. Exon 9 mut = mutation in only exon 9; Exon 20 mut = mutation in only exon 20; WT = wild-type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Samuels Y, Diaz LA, Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561–573. - PubMed
    1. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. - PubMed
    1. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41(11):1649–1654. - PubMed
    1. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16(3):790–799. - PubMed
    1. Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat. 2008;29(2):284–288. - PubMed

Publication types

MeSH terms

Associated data

Grants and funding